title: Effects of administration of exogenous growth factors on biomechanical properties of the elongation-type anterior cruciate ligament injury with partial laceration.
abstract: BACKGROUND
  No studies have been conducted to clarify the in vivo effect of growth factor application on healing in the injured anterior cruciate ligament.
  
  
  OBJECTIVE
  Administration of exogenous growth factors significantly increases the structural properties of the injured anterior cruciate ligament.
  
  
  METHODS
  Controlled laboratory study.
  
  
  METHODS
  Thirty-six rabbits were randomly divided into 4 groups of 9 animals each after an overstretched injury was made in the right anterior cruciate ligament. In group 1, no treatment was applied around the injured anterior cruciate ligament. In group 2, 0.2 mL fibrin sealant was applied around it. In group 3, 4 ng transforming growth factor-beta1 mixed with 0.2 mL fibrin sealant was applied. In group 4, 20 microg platelet-derived growth factor-BB mixed with 0.2 mL fibrin sealant was applied. Each rabbit was sacrificed at 12 weeks after the surgery. In addition, 9 knees randomly harvested from all the left knees were used to obtain normal control data. The femur-anterior cruciate ligament-tibia complex specimens were biomechanically and histologically evaluated.
  
  
  RESULTS
  Concerning the maximum load and the stiffness, group 3 was significantly greater than groups 1 and 2, whereas there were no significant differences among groups 1, 2, and 4. Groups 1, 2, 3, and 4 were significantly lower than the control group.
  
  
  CONCLUSIONS
  The application of 4 ng transforming growth factor-beta1 significantly enhances healing in the injured anterior cruciate ligament.
  
  
  CONCLUSIONS
  Administration of certain growth factors is of value to be studied as one of the future therapeutic options for the overstretched anterior cruciate ligament injury.
authors.affiliation: Department of Sports Medicine & Joint Reconstruction Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
authors.forename: Eiji
authors.initials: E
authors.lastname: Kondo
authors.forename: Kazunori
authors.initials: K
authors.lastname: Yasuda
authors.forename: Masanori
authors.initials: M
authors.lastname: Yamanaka
authors.forename: Akio
authors.initials: A
authors.lastname: Minami
authors.forename: Harukazu
authors.initials: H
authors.lastname: Tohyama
mesh_terms: D000818:Animals; D000070598:Anterior Cruciate Ligament Injuries; D000077214:Becaplermin; D001696:Biomechanical Phenomena; D005260:Female; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use; D022125:Lacerations / Q000503:physiopathology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D020574:Proto-Oncogene Proteins c-sis; D011817:Rabbits; D011994:Recombinant Proteins / Q000494:pharmacology; D012421:Rupture; D013718:Tensile Strength; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D053773:Transforming Growth Factor beta1; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
chemical_list: D015718:Fibrin Tissue Adhesive; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D000077214:Becaplermin